The 3rd Annual Biosimilars conference

Wednesday 18 and Thursday 19 February 2009, Amsterdam, The Netherlands

Within the next two years, pharma market forecasts predict that biopharmaceuticals will amount to more than 50% of newly approved medicines. In addition to a growing market share, a substantial number of major biotechnology-based drugs will come off patent and enable the development of new biosimilar products.

While this facilitates a great range of business opportunities, biosimilar manufacturers face high economic risk and need to come up with innovative business models. In addition, it is crucial for them to ensure that their R&D and production processes guarantee safety and efficacy of their products. As some regulatory issues like interchangeability have not been resolved, manufacturers are particularly forced to come up with a strong and innovative marketing strategy convincing physicians and handling pricing as well as reimbursement issues effectively with regulatory authorities.

VIBevents ’ 3rd annual Biosimilars conference being held on 18-19 February in Amsterdam aims to establish solutions to both developmental and strategic issues. Through case study driven presentations from leading pharma, biotech and generics manufacturers and a series of interactive roundtable discussions, this event will provide best practice solutions to help you resolve your existing and upcoming challenges in the market.

Read more...

• Croatia - Pharmaceuticals and Biotechnology (18/10/2008)
• EU Pharmaceutical Forum (11/10/2008)
• DOXORUBICIN (09/09/2008)

• Sales Force Effectiveness Europe (07/11/2008)

---